Identifying susceptibility genes for prostate cancer - A family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-β

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 8, 2005, Pages 2035-2039

  Douglas, Julie A ^a   Zuhlke, Kimberly A ^a   Beebe Dimmer, Jennifer ^a   Levin, Albert M ^a   Gruber, Stephen B ^a,b   Wood, David P ^a   Cooney, Kathleen A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; AROMATASE; CYTOCHROME P450 11A1; CYTOCHROME P450 17; CYTOCHROME P450 ISOENZYME; ESTRADIOL; GENE PRODUCT; LUTEINIZING HORMONE BETA SUBUNIT; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYP11A1 GENE; CYP17 GENE; CYP19 GENE; DISCORDANT SIBLING PAIR; FAMILY STUDY; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LH BETA GENE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION STRUCTURE; PRIORITY JOURNAL; PROSTATE CANCER; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE METABOLISM;

AROMATASE; CASE-CONTROL STUDIES; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; FAMILY; GENOTYPE; HUMANS; LOGISTIC MODELS; LUTEINIZING HORMONE, BETA SUBUNIT; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; VARIATION (GENETICS);

EID: 23844557117     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0170     Document Type: Article

References (38)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274:1371-4.
3. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175-9.
4. Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998;62:1416-24.
5. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64:776-87.
6. Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
7. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67:1367-75.
8. Simard J, Dumont M, Labuda D, et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 2003;10:225-59.
9. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ. Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate 2003; 57:261-9.
10. Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-80.
11. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPCl. Nat Genet 2002;30:181-4.
12. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
13. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12.
14. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-8.
15. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998; 58:4497-504.
16. Durocher F, Morissette J, Simard J. Genetic linkage mapping of the CYF11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. Fharmacogenetics 1998;8:49-53.
17. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450cl7 (steroid 17 α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987;6:439-48.
18. Voigt KD, Bartsch W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 1986;25:749-57.
19. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240-51.
20. Gsur A, Bernhofer G, Hinteregger S, et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-7.
21. Habuchi T, Liqing Z, Suzuki T, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60:5710-3.
22. Kittles RA, Panguluri RK, Chen W, et al. Cypl7 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10:943-7.
23. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-31.
24. Stanford JL, Noonan EA, Iwasaki L, et al. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:243-7.
25. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9:635-9.
26. Yamada Y, Watanabe M, Murata M, et al. Impact of generic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001;92:683-6.
27. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-7.
28. Suzuki K, Nakazato H, Matsui H, et al. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 2003;23:4941-6.
29. Kumazawa T, Tsuchiya N, Wang L, et al. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer 2004;110:140-4.
30. Elkins DA, Yokomizo A, Thibodeau SN, et al. Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer. Prostate 2003;56:30-6.
31. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280-3.
32. Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000;19 Suppl 1:S36-42.
33. Rabinowitz D, Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum Hered 2000;50:211-23.
34. Siegmund KD, Langholz B, Kraft P, Thomas DC. Testing linkage disequilibrium in sibships. Am J Hum Genet 2000;67:244-8.
35. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ. Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate 2003; 57:261-9.
36. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998; 26:362-7.
37. Stram DO, Leigh PC, Bretsky P, et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-90.
38. Beebe-Dimmer JL, Wood DP Jr, Gruber SB, et al. Risk perception and concern among brothers of men with prostate carcinoma. Cancer 2004;100:1537-44.